[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341050-105":59,"doc-detail-341050-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","fhnd004-inhibits-malignant-proliferation-of-multiple-myeloma-by-targeting-pdz-binding-kinase-in-mapk-pathway","FHND004 inhibits malignant proliferation of multiple myeloma by targeting PDZ-binding kinase in MAPK pathway","","FHND004 is a newly modified small-molecule inhibitor derived from the third-generation EGFR-TKI AZD9291 (Osimertinib), designed to act through an EGFR-kinase-independent route. Pre-clinical cell assays show FHND004 and FHND008 suppress multiple myeloma cell proliferation and induce apoptosis. RNA-seq and protein-chip analyses implicate the MAPK signaling pathway and identify PBK (PDZ-binding kinase) as a target. Molecular docking, MST, and mutational verification confirm PBK–FHND004 interaction. Public datasets link high PBK expression to poor outcomes, and mechanistic studies demonstrate PBK downregulation reduces ERK1/2 phosphorylation, restraining tumor growth.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/fhnd004-inhibits-malignant-proliferation-of-multiple-myeloma-by-targeting-pdz-binding-kinase-in-mapk-pathway/341050/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/fhnd004-inhibits-malignant-proliferation-of-multiple-myeloma-by-targeting-pdz-binding-kinase-in-mapk-pathway/341050.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What therapeutic effect does FHND004 show in multiple myeloma?","Question",{"text":112,"@type":113},"FHND004 significantly inhibits multiple myeloma cell proliferation and promotes apoptosis in cell-based assays, and it suppresses survival and tumor growth in mouse and PDX models.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which pathway and target are identified as central to FHND004’s action?",{"text":117,"@type":113},"RNA-seq indicates involvement of the MAPK signaling pathway, and a protein-chip screen identifies PDZ-binding kinase (PBK) as a potential drug target.",{"name":119,"@type":110,"acceptedAnswer":120},"How does FHND004 interact with PBK and what mechanistic evidence supports this?",{"text":121,"@type":113},"PBK–FHND004 binding is verified by molecular docking and microscale thermophoresis (MST) with site mutation (N124/D125). Mechanistically, FHND004 downregulates PBK expression and mediates ERK1/2 phosphorylation changes in the MAPK pathway.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341050,1790252087,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www.aging-us.com](www.aging-us.com) AGING 2024, Vol. 16, No. 5  \nResearch Paper  \nFHND004 inhibits malignant proliferation of multiple myeloma by targeting PDZ-binding kinase in MAPK pathway  \nHongjie Wu1,2,*, Jinjun Qian2,*, Lianxin Zhou2, Tingting Hu2, Yuanjiao Zhang2, Chen Wang2, Ye Yang2, Chunyan Gu 1,2  \n1 Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China 2School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China *Equal contribution  \nCorrespondence to: Ye Yang, Chunyan Gu; [email:](email: yangye876@sina.com)[ ](email: yangye876@sina.com)[yangye876@sina.com](email: yangye876@sina.com), [https://orcid.org/0000-0003-0228-5102](https://orcid.org/0000-0003-0228-5102); [guchunyan@njucm.edu.cn](guchunyan@njucm.edu.cn)  \nKeywords: multiple myeloma, PDZ-binding kinase, MAPK signaling, FHND004, proliferation  \nReceived: November 1, 2023 Accepted: February 8, 2024 Published: March 7, 2024  \nCopyright: © 2024 Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nABSTRACT  \nInhibitors of Epidermal growth factor receptor tyrosine kinase (EGFR-TKIs) are producing impressive benefits to responsive types of cancers but challenged with drug resistances. FHND drugs are newly modified small molecule inhibitors based on the third-generation EGFR-TKI AZD9291 (Osimertinib) that are mainly for targeting the mutant-selective EGFR, particularly for the non-small cell lung cancer (NSCLC) . Successful applications of EGFR-TKIs to other cancers are less certain, thus the present pre-clinical study aims to explore the anticancer effect and downstream targets of FHND in multiple myeloma (MM), which is an incurable hematological malignancy and reported to be insensitive to first/second generation EGFR-TKIs (Gefitinib/Afatinib) . Cell-based assays revealed that FHND004 and FHND008 significantly inhibited MM cell proliferation and promoted apoptosis. The RNA-seq identified the involvement of the MAPK signaling pathway. The protein chip screened PDZ-binding kinase (PBK) as a potential drug target. The interaction between PBK and FHND004 was verified by molecular docking and microscale thermophoresis (MST) assay with site mutation (N124/D125). Moreover, the public clinical datasets showed high expression of PBK was associated with poor clinical outcomes. PBK overexpression evidently promoted the proliferation of two MM cell lines, whereas the FHND004 treatment significantly inhibited survival of 5TMM3VT cell-derived model mice and growth of patient-derived xenograft (PDX) tumors. The mechanistic study showed that FHND004 downregulated PBK expression, thus mediating ERK1/2 phosphorylation in the MAPK pathway. Our study not only demonstrates PBK as a promising novel target of FHND004 to inhibit MM cell proliferation, but also expands the EGFR kinase-independent direction for developing anti-myeloma therapy.  \nINTRODUCTION  \nMultiple myeloma (MM) is a malignancy of plasma cells in the bone marrow, and mainly occurs among older adults (median age around 70) with clinical manifestations such as hypercalcemia, anemia, renal insufficiency, and pathological fractures [1–3] . In the last two decades, the use of novel drugs such as proteasome inhibitors (PI), immunomodulatory drugs, antibody-based targeting immunotherapy, and chimeric  \nantigen receptor (CAR) T-cell therapy have improved the overall survival rate of MM patients. However, it remains incurable as most patients unavoidably relapsed and became drug resistance [4–6] . Thus, there is an urgent need to find more potential drugs/targets and develop more therapeutic strategies.  \nSince the approval of the first designed kinase inhibitor (imatinib) in 2001 and the first anti-EGFR inhibitor (Gefitinib)","cbCaiji3weUJSRhu","https://ap.wps.com/l/cbCaiji3weUJSRhu","pdf",3244408,21,"English","# Abstract\n# Introduction","[{\"question\":\"What therapeutic effect does FHND004 show in multiple myeloma?\",\"answer\":\"FHND004 significantly inhibits multiple myeloma cell proliferation and promotes apoptosis in cell-based assays, and it suppresses survival and tumor growth in mouse and PDX models.\"},{\"question\":\"Which pathway and target are identified as central to FHND004’s action?\",\"answer\":\"RNA-seq indicates involvement of the MAPK signaling pathway, and a protein-chip screen identifies PDZ-binding kinase (PBK) as a potential drug target.\"},{\"question\":\"How does FHND004 interact with PBK and what mechanistic evidence supports this?\",\"answer\":\"PBK–FHND004 binding is verified by molecular docking and microscale thermophoresis (MST) with site mutation (N124/D125). Mechanistically, FHND004 downregulates PBK expression and mediates ERK1/2 phosphorylation changes in the MAPK pathway.\"}]","FHND004 inhibits malignant proliferation of multiple myeloma by targeting PDZ-binding kinase in MAPK pathway | PDF",1790040099,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c044a51eff3df09c5c215596c5f8059.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba802d912a29ef665de506e320376496.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42d355061f26d5462e5571fb6f617f8a.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac69216da74d0ea728e0ebfdeb26d560.webp",980,1268]